Raw material crystal lump capable of influencing in-vitro release and in-vivo absorption of nifedipine preparation and preparation method of raw material crystal lump
By preparing granular nifedipine raw materials with uniform particle size, and combining specific components and processes, the problems of unstable dissolution rate and bioavailability of nifedipine sustained-release tablets were solved, and the stability and controllability of the formulation were achieved.
Patent Information
- Application Number
- CN202411236233.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-29
AI Technical Summary
The inconsistent crystal forms of raw materials used in existing nifedipine sustained-release tablets lead to unstable in vitro dissolution rates and bioavailability, affecting the industrialization process.
Nifedipine is prepared using granular raw material with a particle size D90 of 70-90 μm through recrystallization, drying and other steps. Combined with microcrystalline cellulose, lactose and other components, nifedipine sustained-release tablets are prepared to control the drug release rate and bioavailability.
This achieves controllable stability and bioavailability of the formulation, reduces batch-to-batch variability, and improves the reliability of clinical studies.
Smart Images

Figure CN119039212A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a raw material crystal habit affecting the in vitro release and in vivo absorption of a nifedipine preparation and a preparation method thereof. Background Art
[0002] Nifedipine is a first-generation dihydropyridine calcium channel blocker. This product is composed of two fragments, dihydropyridine and nitrobenzene. The dihydropyridine ring is constructed by reaction. It uses p-nitrobenzaldehyde as the starting material and undergoes a Hanstzch reaction with ethyl acetoacetate and ammonia. It was first developed and marketed by Bayer in Germany in 1969. It can selectively inhibit the transmembrane transport of calcium ions into myocardial cells and smooth muscle cells, and inhibit the release of calcium ions from cells without changing the plasma calcium ion concentration.
[0003] Clinically, nifedipine is mainly used for various types of hypertension and angina pectoris. Until the mid-1980s, nifedipine became one of the world's best-selling drugs. After years of clinical application and in-depth research, nifedipine has become one of the first choice drugs for the treatment of hypertension and angina pectoris in clinical practice. In 1985, the twice-daily Adalat-L nifedipine sustained-release tablets were launched in Japan, and in 1998, Bayer developed the once-daily Adalat-CR sustained-release tablets.
[0004] At present, the release rate of nifedipine sustained-release tablets is mainly controlled by controlling the particle size of the raw materials. The existing nifedipine raw materials on the market have the same crystal form, but the initial particle size and morphology are different. The particle morphology of the raw materials is mostly irregular block crystal habits, and the appearance of a single crystal is mostly broken. The crystal surface is rough and there are many cross-sections. In addition, the crystal morphology varies greatly between different batches, making it difficult to stably control the dissolution rate of the preparation in vitro, which seriously affects the industrialization process of its sustained-release preparation.
[0005] At present, the control of the raw material dissolution rate is generally achieved by optimizing and adjusting the particle size and crystal form of nifedipine, while there are few studies on the regulation of the raw material crystal morphology. Invention patent CN112592311A discloses a nifedipine A crystal block habit and a controlled release tablet composition thereof, wherein the controlled release tablet composition contains hypromellose and the nifedipine A crystal habit, wherein the nifedipine A crystal form is a cubic block, and its length, width and thickness ratio is 4-1:2-1:1, and its particle size range is Dv(90)120-240μm. Although the patent has conducted relevant in vitro studies on crystal habit and solved the problem that the dissolution rate of controlled release preparations caused by crystal habit is difficult to stably control, the difference in in vivo bioavailability caused by crystal habit has not been studied. The controllability of the quality and efficacy of the drug includes the in vitro dissolution rate and in vivo absorption, and the consistency of the in vitro dissolution rate does not mean the consistency of in vivo absorption. Therefore, the effect of crystal habit on in vivo absorption is crucial. Summary of the invention
[0006] The present invention proposes raw material crystal habits that affect the in vitro release and in vivo absorption of nifedipine preparations and a preparation method thereof, thereby solving the problems in the related art of the difficulty in regulating the in vitro dissolution rate and bioavailability of nifedipine preparations and the large batch-to-batch differences of products.
[0007] The technical solution of the present invention is as follows: The raw material crystal habit that affects the in vitro release and in vivo absorption of nifedipine preparations is granular, and the particle size D90 is 70~90μm.
[0008] The present invention also provides nifedipine, the crystal habit of which is the above-mentioned crystal habit.
[0009] The present invention also provides a method for preparing nifedipine, comprising the following steps: S1, mixing methanol and crude nifedipine, and then recrystallizing to obtain a refined solution; S2, crystallizing the refined liquid, separating the crystals, and drying to obtain nifedipine.
[0010] As a further technical solution, the mass ratio of the methanol to the crude nifedipine is 5-7:1.
[0011] As a further technical solution, the recrystallization is specifically: heating to reflux, the reflux temperature is 60-70° C., and the time is 0.5-1.5 h.
[0012] As a further technical solution, the crystallization temperature is 0-10°C and the time is 0.5-1.5h.
[0013] As a further technical solution, the drying temperature is 55-65°C, the drying time is 10-15 hours, and the vacuum degree is ≤-0.08MPa.
[0014] The present invention also provides a nifedipine sustained-release tablet, the raw materials of which include the nifedipine or the nifedipine prepared by the preparation method.
[0015] As a further technical solution, the nifedipine sustained-release tablet comprises the following raw materials in parts by weight: 150-250 parts of nifedipine, 320-360 parts of microcrystalline cellulose, 80-120 parts of lactose, 130-150 parts of binder, 8-12 parts of surfactant, 1-3 parts of lubricant, and 20-40 parts of coating powder.
[0016] The surfactant in the present invention can be any surfactant in the art, preferably Tween 80.
[0017] The adhesive in the present invention can be any adhesive in the art, preferably starch.
[0018] The lubricant in the present invention can be any lubricant in the art, preferably magnesium stearate.
[0019] As a further technical solution, the following raw materials are included in parts by mass: 200 parts of nifedipine, 348 parts of microcrystalline cellulose, 100 parts of lactose, 140 parts of binder, 10 parts of surfactant, 2 parts of lubricant, and 30 parts of coating powder.
[0020] As a further technical solution, the present invention comprises the following raw materials in parts by weight: 200 parts of nifedipine, 348 parts of microcrystalline cellulose, 100 parts of lactose, 140 parts of starch, 10 parts of Tween 80, 2 parts of magnesium stearate, and 30 parts of coating powder.
[0021] The present invention also provides a method for preparing a nifedipine sustained-release tablet, comprising the following steps: A1. After mixing the binder with water, add a surfactant and mix well to obtain a slurry; A2, crushing nifedipine, mixing it with microcrystalline cellulose, lactose and the slurry, and granulating to obtain granules; A3. Evenly mix the granules and lubricant, compress the granules, and coat the granules to obtain nifedipine sustained-release tablets.
[0022] The working principle and beneficial effects of the present invention are: 1. The present invention provides a nifedipine crystal habit that meets the requirements of the preparation process. The crystal form is complete, the particle size distribution is relatively uniform, the hardness is large, the tolerance to pressure is high, and it is not easy to break or adsorb during the preparation process, thereby achieving the regulation of dissolution rate and bioavailability and reducing the batch-to-batch differences of the preparation product. In addition, the inventors have also systematically studied the crystal morphology of nifedipine raw materials. By comparing different forms of nifedipine from multiple angles such as morphology, particle size, in vitro dissolution to in vivo bioequivalence tests, it is found that different raw material crystal forms are consistent, and the particle size after crushing is consistent, but the initial crystal habit is inconsistent, which will lead to inconsistent drug release rate and bioavailability in vivo. Among them, the fluidity and tolerance to pressure of spherical and blocky particles are far better than those of needle-shaped particles, and the fluidity of flaky and scaly particles is poor, and it is easy to break, such as tableting process, aggregation and precipitation, such as mixing process, etc. in the preparation process. In addition, the morphology of the drug will also affect the dissolution rate of the drug. The dissolution rate of blocky particles of the same particle size is usually less than that of flaky particles.
[0023] 2. The sustained-release tablets prepared from nifedipine with a specific crystal habit provided by the present invention have high stability, achieve controllable dissolution rate and bioavailability, greatly reduce batch-to-batch differences in preparation products, and reduce the risks of clinical research. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments.
[0025] Figure 1 This is an image of the nifedipine granular crystalline bulk drug substance prepared in Example 1 under a microscope; Figure 2 This is an image of the rod-shaped crystalline bulk drug of nifedipine prepared in Comparative Example 1 under a microscope; Figure 3 This is an image of the nifedipine scaly crystalline bulk drug prepared in Comparative Example 2 under a microscope; Figure 4 This is the XRD pattern of nifedipine crystalline bulk drug; In the figure, a is the rod-shaped crystalline API of nifedipine, b is the scale-shaped crystalline API of nifedipine, and c is the granular crystalline API of nifedipine. DETAILED DESCRIPTION
[0026] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0027] The parameters of the raw materials in the following examples and comparative examples are as follows: The content of nifedipine in the crude nifedipine is 99.8%.
[0028] Example 1 The nifedipine API is a granular crystalline API with a particle size D90 of 70~90μm (laser particle size analyzer). The preparation method is as follows: 3.6 kg of methanol was added to the reactor, stirring was started, 0.6 kg of crude nifedipine was added and mixed, the temperature was raised to 65°C and refluxed for 1 hour for recrystallization to obtain a refined liquid; the refined liquid was filtered through a filter press device into a stainless steel crystallization kettle, cooled to 5°C, kept warm and stirred for crystallization for 1 hour, transferred to a centrifuge and centrifuged until no mother liquid flowed out, and the material was discharged after drying and put into a double cone rotary vacuum dryer, and the temperature was not raised for cold extraction for 2 hours. After the end, the material temperature was raised to 60°C, and the vacuum degree was controlled at -0.08Mpa and dried for 12 hours to obtain 0.48 kg of granular crystalline API with a particle size D90 of 70~90μm (the microscope image is as shown in FIG. Figure 1 shown); Preparation of nifedipine sustained-release tablets: A0. Add 30 parts of the coating powder into pure water and disperse evenly to obtain a coating agent with a mass concentration of 12%; A1. Mix 140 parts of starch with water to prepare a starch slurry with a mass concentration of 8%, add 10 parts of Tween 80 and stir to mix evenly to obtain a slurry; A2, 200 parts of nifedipine API were crushed to a D90 of 40 μm, and then added to a wet granulator with 348 parts of microcrystalline cellulose and 100 parts of lactose, and the above slurry was added and mixed, and granulation was performed to obtain granules; A3. The above granules were sized, 2 parts of magnesium stearate were added and mixed evenly, and tablets were pressed using a 6 mm round shallow concave punch. The tablets were added into a coating agent for coating, and the coating weight was increased by 4% to obtain nifedipine sustained-release tablets.
[0029] Example 2 The nifedipine API is a granular crystalline API with a particle size D90 of 70~90μm (laser particle size analyzer). The preparation method is as follows: 3 kg of methanol was added to the reactor, stirring was started, 0.6 kg of crude nifedipine was added and mixed, the temperature was raised to 60°C and refluxed for 1.5 hours for recrystallization to obtain a refined liquid; the refined liquid was filtered through a filter press into a stainless steel crystallization kettle, cooled to 0°C, kept warm and stirred for crystallization for 1.5 hours, transferred to a centrifuge and centrifuged until no mother liquid flowed out, dried and discharged, and put into a double cone rotary vacuum dryer, without heating and cold extraction for 2 hours, and after the end, the material temperature was raised to 55°C, the vacuum degree was controlled at -0.05Mpa and dried for 15 hours to obtain 0.4 kg of granular crystalline API with a particle size D90 of 70~90μm; Preparation of nifedipine sustained-release tablets: A0. Add 20 parts of the coating powder into pure water and disperse evenly to obtain a coating agent with a mass concentration of 12%; A1. Mix 130 parts of starch with water to prepare a starch slurry with a mass concentration of 8%, add 8 parts of Tween 80 and stir to mix evenly to obtain a slurry; A2, 150 parts of nifedipine API was crushed to a D90 of 40 μm, and then added to a wet granulator with 320 parts of microcrystalline cellulose and 80 parts of lactose, and then added to the above slurry for mixing, granulation, and obtaining granules; A3. The above granules were sized, 1 part of magnesium stearate was added and mixed evenly, and tablets were pressed using a 6 mm round shallow concave punch, and then added to a coating agent for coating. The coating weight was increased by 4% to obtain nifedipine sustained-release tablets.
[0030] Example 3 The nifedipine API is a granular crystalline API with a particle size D90 of 70~90μm (laser particle size analyzer). The preparation method is as follows: 4.2 kg of methanol was added to the reactor, stirring was started, 0.6 kg of crude nifedipine was added and mixed, the temperature was raised to 70°C and refluxed for 0.5 h for recrystallization to obtain a refined liquid; the refined liquid was filtered through a filter press into a stainless steel crystallization kettle, the temperature was lowered to 10°C, the temperature was kept stirred for crystallization for 0.5 h, the liquid was transferred to a centrifuge and centrifuged until no mother liquid flowed out, the material was dried and discharged, and the material was put into a double cone rotary vacuum dryer, and the temperature was not raised for cold extraction for 2 h. After the drying, the material temperature was raised to 65°C, the vacuum degree was controlled at -0.08 MPa and dried for 10 h, and 0.35 kg of granular crystalline API with a particle size D90 of 70-90 μm was obtained; Preparation of nifedipine sustained-release tablets: A0. Add 40 parts of the coating powder into pure water and disperse evenly to obtain a coating agent with a mass concentration of 12%; A1. Mix 150 parts of starch with water to prepare a starch slurry with a mass concentration of 8%, add 12 parts of Tween 80 and stir to mix evenly to obtain a slurry; A2, 250 parts of nifedipine API were crushed to a D90 of 40 μm, and then added to a wet granulator with 360 parts of microcrystalline cellulose and 120 parts of lactose, and the above slurry was added to mix, granulation was performed, and granules were obtained; A3. The above granules were sized, 3 parts of magnesium stearate were added and mixed evenly, and tablets were pressed using a 6 mm round shallow concave punch. The tablets were added into a coating agent for coating, and the coating weight was increased by 4% to obtain nifedipine sustained-release tablets.
[0031] Comparative Example 1 The only difference from Example 1 is that the nifedipine bulk drug is a rod-shaped (laser particle size analyzer) crystalline bulk drug of nifedipine, the ratio of its length to diameter is 3:1, and the preparation method is as follows: 50g of nifedipine was added to a crystallization reaction bottle containing 1000g of ethanol and water mixed solvent (the volume ratio of ethanol to water was 8:2), and after stirring at 60℃ for 30min to dissolve, purified water was added to the crystallization reaction bottle for recrystallization at a rate of 1.7mL / min. When the mass fraction of water in the solution was 25%, the addition of purified water was stopped; activated carbon was added for decolorization, and the filtrate was transferred to the crystallization reaction bottle, cooled to 40℃ within 60min, and kept warm for 3h, and then cooled to 10℃ within 180min, and kept warm for 3h; filtered, the filter cake was washed with methanol, and dried at 50℃ and normal pressure for 12h to obtain 42.8g of nifedipine rod-shaped crystals (microscope image as shown in Figure 2). Figure 2 as shown).
[0032] Comparative Example 2 The only difference from Example 1 is that the nifedipine bulk drug is a nifedipine squamous (laser particle size analyzer) crystalline bulk drug, the ratio of its length: width: thickness is 1:0.8:0.2, and the preparation method is as follows: 50g of nifedipine was added to a crystallization reaction bottle containing 1000g of a mixed solvent of methanol and water (the volume ratio of methanol to water was 8:2), and after stirring at 45°C for 30min to dissolve, purified water was added to the crystallization reaction bottle for recrystallization at a rate of 2.5mL / min. When the mass fraction of water in the solution was 40%, the addition of purified water was stopped; the temperature was lowered to 20°C within 30min and then kept warm for 1h for crystal growth, and then the temperature was lowered to 5°C within 30min and kept warm for 1h for crystal growth; the filter cake was washed with methanol and dried at 60°C under normal pressure for 8h to obtain 41.98g of nifedipine scaly crystals (microscope image as shown in FIG. Figure 3 as shown).
[0033] (1) Dissolution test: The aqueous solution of 0.3wt% polysorbate 80 was selected as the most discriminating curve, and the formulation process was evaluated.
[0034] Light-proof operation: Take the nifedipine sustained-release tablets obtained in Example 1 and Comparative Examples 1-2 respectively, and follow the dissolution and release determination method (Chinese Pharmacopoeia 2020 Edition Four General Rules 0931 Second Method), with 900mL of 0.3wt% polysorbate 80 aqueous solution as the dissolution medium, the speed is 75 revolutions per minute, operate according to the law, and take samples after 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, and 24h, and take 5mL of solution respectively, filter, and replenish the same temperature and volume of dissolution medium in time as the test solution. Take 28mg of nifedipine reference substance separately, place it in a 100mL volumetric flask, add 50mL of methanol to dissolve it, dilute it to the scale with water, shake it well, measure 2mL and place it in a 25mL volumetric flask, dilute it to the scale with dissolution medium, shake it well, and use it as the reference solution. According to the chromatographic conditions under the content determination item, 50 μL of the test solution and the reference solution were measured and injected into the liquid chromatograph respectively, and the chromatograms were recorded; the dissolution amount at different times was calculated by the peak area according to the external standard method. The in vitro dissolution data are recorded in Table 1.
[0035] Table 1 In vitro dissolution data
[0036] It can be seen from Table 1 that there is basically no difference in the in vitro dissolution and release of the sustained-release tablets prepared by the three crystal habits, and the f2 values are all greater than 70.
[0037] (2) In vivo bioequivalence study (fasting) n=20: Experimental method: Subjects were randomly assigned to one of the two dosing order groups (Group A, Group B) at a ratio of 1:1. In the first cycle, 10 subjects took the test preparation (T) 20 mg orally on an empty stomach with 240 mL of warm water, and the other 10 subjects took the reference preparation (R, Adalat® retard) 20 mg orally on an empty stomach with 240 mL of warm water. The dosing was crossed after 4 days. The pharmacist of the Phase I clinical research laboratory allocated the study drug for each stage of the study according to the randomization list.
[0038] The in vivo bioequivalence test data are recorded in Tables 2~4.
[0039] Table 2 In vivo bioequivalence data of Example 1
[0040] Table 3 In vivo bioequivalence data of comparative example 1
[0041] Table 4 In vivo bioequivalence data of comparative example 2
[0042] It can be seen from Tables 2 to 4 that the results of the sustained-release tablets prepared by the three crystal habits in the in vivo bioequivalence test are quite different. Comparative Examples 1 to 2 exceed the range of 80.00% to 125.00%, which do not meet the acceptance criteria for bioequivalence, that is, the test preparation and the reference preparation are not bioequivalent under fasting conditions, while Example 1 is within the range of 80.00% to 125.00%, which meets the acceptance criteria for bioequivalence, that is, the test preparation and the reference preparation are bioequivalent under fasting conditions.
[0043] The nifedipine crystalline bulk drug obtained in Example 1 and Comparative Examples 1-2 was characterized by XRD. The XRD patterns are as follows: Figure 4 As shown; in the figure, a is the rod-shaped crystalline bulk drug of nifedipine prepared in Comparative Example 1, b is the scaly crystalline bulk drug of nifedipine prepared in Comparative Example 2, and c is the granular crystalline bulk drug of nifedipine prepared in Example 1. The main characteristic peaks 2θ of the three types of crystalline bulk drugs of nifedipine are recorded in Table 5.
[0044] Table 5 Three types of crystalline bulk drugs of nifedipine
[0045] Depend on Figure 4 As can be seen from Table 5, the crystal forms of the three types of nifedipine crystalline raw materials are consistent.
[0046] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A raw material crystal habit affecting the in vitro release and in vivo absorption of a nifedipine preparation, characterized in that: It is granular with a particle size D90 of 70~90μm.
2. A nifedipine, characterized in that: The crystal habit is the crystal habit described in claim 1.
3. The method for preparing nifedipine according to claim 2, characterized in that: The following steps are involved: S1, mixing methanol and crude nifedipine, and then recrystallizing to obtain a refined solution; S2, crystallizing the refined liquid, separating the crystals, and drying to obtain nifedipine.
4. The method for preparing nifedipine according to claim 3, characterized in that: The mass ratio of the methanol to the crude nifedipine is 5-7:
1.
5. The method for preparing nifedipine according to claim 3, characterized in that: The recrystallization is specifically as follows: heating to reflux, wherein the reflux temperature is 60-70° C. and the time is 0.5-1.5 h.
6. The method for preparing nifedipine according to claim 3, characterized in that: The crystallization temperature is 0-10°C and the crystallization time is 0.5-1.5h.
7. The method for preparing nifedipine according to claim 3, characterized in that: The drying temperature is 55-65° C., the drying time is 10-15 hours, and the vacuum degree is ≤-0.08 MPa.
8. A nifedipine sustained-release tablet, characterized in that: The raw material includes the nifedipine described in claim 2 or the nifedipine prepared by the preparation method described in any one of claims 3 to 7.
9. The nifedipine sustained-release tablet according to claim 8, characterized in that: The invention comprises the following raw materials in parts by weight: 150-250 parts of nifedipine, 320-360 parts of microcrystalline cellulose, 80-120 parts of lactose, 130-150 parts of binder, 8-12 parts of surfactant, 1-3 parts of lubricant and 20-40 parts of coating powder.
10. The method for preparing a nifedipine sustained-release tablet according to claim 9, characterized in that: The following steps are involved: A1. After mixing the binder with water, add a surfactant and mix evenly to obtain a slurry; A2, grinding nifedipine, mixing with microcrystalline cellulose, lactose and the slurry, granulating to obtain granules; A3. Evenly mix the granules and lubricant, compress the granules, and coat the granules to obtain nifedipine sustained-release tablets.
